In breast and lung cancers, p300/CBP inhibition can restrict tumor progression by impairing the function of immunosuppressive cells such as regulatory T cells and MDSCs in tumor microenvironments (Liu et al., 2013; de Almeida Nagata et al., 2019). The gene discussed is EP300; the disease is neoplasm.